Undisclosed amylin agonist
/ Ambrosia Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 31, 2026
Ambrosia Biosciences Announces $100 Million Oversubscribed Series B Financing to Advance Novel Small Molecule Cardiometabolic Pipeline
(PRNewswire)
- "Proceeds from the financing will support: Advancement of the Company's novel oral small molecule GLP-1 into a Phase 1 clinical trial; Continued development of the Company's other small molecule programs, including GIP and amylin."
Financing • Metabolic Disorders • Obesity
1 to 1
Of
1
Go to page
1